keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic breast cancer

keyword
https://www.readbyqxmd.com/read/29161698/a-comparison-of-three-methods-for-the-detection-of-circulating-tumor-cells-in-patients-with-early-and-metastatic-breast-cancer
#1
Eleni Politaki, Sofia Agelaki, Stella Apostolaki, Dora Hatzidaki, Areti Strati, Filippos Koinis, Maria Perraki, Georgia Saloustrou, Giannis Stoupis, Galatea Kallergi, Maria Spiliotaki, Tereza Skaltsi, Evi Lianidou, Vassilis Georgoulias, Dimitrios Mavroudis
BACKGROUND: We directly compared CTC detection rates and prognostic significance, using three different methods in patients with breast cancer (BC). METHODS: Early (n=200) and metastatic (n=164) patients were evaluated before initiating adjuvant or first-line chemotherapy, using the CellSearchTM System, an RT-qPCR for CK-19 mRNA detection and by double immunofluorescence (IF) microscopy using A45-B/B3 and CD45 antibodies. RESULTS: Using the CellSearchTM System, 37% and 16...
November 20, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29161652/impact-of-body-mass-index-on-the-clinical-outcomes-of-patients-with-her2-positive-metastatic-breast-cancer
#2
Samuel Martel, Elena Poletto, Arlindo R Ferreira, Matteo Lambertini, Federico Sottotetti, Ilaria Bertolini, Filippo Montemurro, Antonio Bernardo, Emanuela Risi, Elisa Zanardi, Serena Ziliani, Silvia Mura, Chiara Dellepiane, Lucia Del Mastro, Alessandro Marco Minisini, Fabio Puglisi
BACKGROUND: Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). METHODS: This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens...
November 18, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29161296/epithelial-periostin-expression-is-correlated-with-poor-survival-in-patients-with-invasive-breast-carcinoma
#3
Ga-Eon Kim, Ji Shin Lee, Min Ho Park, Jung Han Yoon
Invasion and metastasis are direct causes of mortality in patients with breast cancer and require reciprocal interactions between cancer cells and the extracellular matrix (ECM). Periostin, a fasciclin-containing adhesive ECM glycoprotein, is frequently overexpressed in various types of human cancer, and its overexpression in cancer-associated stroma and/or cancer cells is usually associated with poor clinical outcomes. However, the expression of periostin in the successive steps of breast tumorigenesis and its association with outcome variables have not been well established in breast carcinoma...
2017: PloS One
https://www.readbyqxmd.com/read/29160213/cutaneous-metastases-of-internal-malignancies-an-experience-from-a-single-institution
#4
Elena Guanziroli, Antonella Coggi, Luigia Venegoni, Daniele Fanoni, Giulia Ercoli, Francesca Boggio, Stefano Veraldi, Emilio Berti, Raffaele Gianotti, Stefano Ferrero, Alessandro Del Gobbo
BACKGROUND: Cutaneous metastases represent 2% of all skin tumours. Their recognition can be challenging, as they may present with different clinical features, with consequent frequent delay and failure in diagnosis. OBJECTIVES: To review our series of cutaneous metastatic lesions, analyse their frequency according to patient gender, histotype, localization of the primary tumour, and site of cutaneous metastasis, and correlate this data with clinicopathological parameters...
November 21, 2017: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/29159760/body-mass-index-age-at-breast-cancer-diagnosis-and-breast-cancer-subtype-a-cross-sectional-study
#5
O Brouckaert, K Van Asten, A Laenen, A Soubry, A Smeets, I Nevelstreen, I Vergote, H Wildiers, R Paridaens, E Van Limbergen, C Weltens, P Moerman, G Floris, P Neven
PURPOSE: Evidence suggests that premenopausal obesity decreases and postmenopausal obesity increases breast cancer risk. Because it is not well known whether this is subtype dependent, we studied the association between body mass index (BMI) and age at breast cancer diagnosis, or the probability of being diagnosed with a specific breast cancer phenotype, by menopausal status. METHODS: All patients with non-metastatic operable breast cancer from the University Hospital Leuven diagnosed between January 1, 2000 and December 31, 2013 were included (n = 7020) in this cross-sectional study...
November 20, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29159517/correction-to-phase-i-dose-finding-study-of-eribulin-and-capecitabine-for-metastatic-breast-cancer-jbcrg-18-cape-study
#6
Masaya Hattori, Hiroshi Ishiguro, Norikazu Masuda, Akiyo Yoshimura, Shoichiro Ohtani, Hiroyuki Yasojima, Satoshi Morita, Shinji Ohno, Hiroji Iwata
The article "Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study", written by Masaya Hattori, Hiroshi Ishiguro, Norikazu Masuda, Akiyo Yoshimura, Shoichiro Ohtani, Hiroyuki Yasojima, Satoshi Morita, Shinji Ohno, and Hiroji Iwata, was originally published electronically on the publisher's Internet portal (currently SpringerLink) on 31 August 2017 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on [9 November 2017] to...
November 20, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29158825/noninvasive-imaging-of-cd206-positive-m2-macrophages-as-an-early-biomarker-for-post-chemotherapy-tumor-relapse-and-lymph-node-metastasis
#7
Chenran Zhang, Xinhe Yu, Liquan Gao, Yang Zhao, Jianhao Lai, Dehua Lu, Rui Bao, Bing Jia, Lijun Zhong, Fan Wang, Zhaofei Liu
Tumor relapse after initial regression post-chemotherapy is a major challenge in cancer treatment, as it usually leads to local-regional recurrence or inoperable distant metastasis. M2 macrophages diminish the tumor-inhibitory effect of chemotherapy and correlate with distant metastasis and poor prognosis. In this study, we investigated whether molecular imaging of M2 macrophages could serve as an early biomarker for tumor relapse after chemotherapy and tumor lymph node metastasis in preclinical mouse models...
2017: Theranostics
https://www.readbyqxmd.com/read/29158820/ph-sensitive-nano-complexes-overcome-drug-resistance-and-inhibit-metastasis-of-breast-cancer-by-silencing-akt-expression
#8
Jieying Yin, Tianqun Lang, Dongmei Cun, Zhong Zheng, Yan Huang, Qi Yin, Haijun Yu, Yaping Li
The therapy of breast cancer is encumbered by drug resistance and metastasis, which can be due to a defective PI3K/AKT/mTOR signaling pathway. This study was aimed at improving the anti-cancer effect of the chemotherapeutic agent paclitaxel (PTX) on the drug resistant and metastatic breast cancer by co-delivering PTX and a siRNA, siAkt, directed at silencing the Akt expression. Methods: The pH-sensitive amphiphilic polymer, poly [(1,4-butanediol)-diacrylate-β-N, N-diisopropylethylenediamine]-polyethyleneimine (BDP) was synthesized...
2017: Theranostics
https://www.readbyqxmd.com/read/29158783/fascin-expression-is-inversely-correlated-with-breast-cancer-metastasis-suppressor-1-and-predicts-a-worse-survival-outcome-in-node-negative-breast-cancer-patients
#9
Hye Jin Lee, Hee Jung An, Tae Hoen Kim, Gwangil Kim, Haeyoun Kang, Jin Hyung Heo, Ah-Young Kwon, Sewha Kim
Background: Fascin is an actin-bundling protein that promotes cancer cell migration and invasion. By contrast, breast cancer metastasis suppressor 1 (BRMS1) inhibits cancer metastasis by targeting multiple steps of the metastatic cascade. We evaluated whether expression patterns of fascin and BRMS1 correlate with clinicopathological features and patient outcome. Methods: Immunohistochemistry for fascin and BRMS1 was performed using a tissue microarray constructed from 183 human breast cancer tissues. Fascin expression determined by the proportion of stained tumor cells (0: 0-5%, 1: 6-25%, 2: 26-50%, 3: 51-75%, or 4: >75%) and staining intensity (0: negative, 1: weak, 2: moderate, or 3: strong) were multiplied and defined as negative (0-3) or positive (4-12)...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158674/skin-derived-mesenchymal-stem-cells-as-quantum-dot-vehicles-to-tumors
#10
Dominyka Dapkute, Simona Steponkiene, Danute Bulotiene, Liga Saulite, Una Riekstina, Ricardas Rotomskis
Purpose: Cell-mediated delivery of nanoparticles is emerging as a new method of cancer diagnostics and treatment. Due to their inherent regenerative properties, adult mesenchymal stem cells (MSCs) are naturally attracted to wounds and sites of inflammation, as well as tumors. Such characteristics enable MSCs to be used in cellular hitchhiking of nanoparticles. In this study, MSCs extracted from the skin connective tissue were investigated as transporters of semiconductor nanocrystals quantum dots (QDs)...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29158506/the-ikk-nf-%C3%AE%C2%BAb-signaling%C3%A2-pathway-requires-morgana-to-drive-breast-cancer-metastasis
#11
Federica Fusella, Laura Seclì, Elena Busso, Anna Krepelova, Enrico Moiso, Stefania Rocca, Laura Conti, Laura Annaratone, Cristina Rubinetto, Maurizia Mello-Grand, Vijay Singh, Giovanna Chiorino, Lorenzo Silengo, Fiorella Altruda, Emilia Turco, Alessandro Morotti, Salvatore Oliviero, Isabella Castellano, Federica Cavallo, Paolo Provero, Guido Tarone, Mara Brancaccio
NF-κB is a transcription factor involved in the regulation of multiple physiological and pathological cellular processes, including inflammation, cell survival, proliferation, and cancer cell metastasis. NF-κB is frequently hyperactivated in several cancers, including triple-negative breast cancer. Here we show that NF-κB activation in breast cancer cells depends on the presence of the CHORDC1 gene product Morgana, a previously unknown component of the IKK complex and essential for IκBα substrate recognition...
November 21, 2017: Nature Communications
https://www.readbyqxmd.com/read/29158314/tumour-adipose-tissue-crosstalk-fuelling-tumour-metastasis-by-extracellular-vesicles
#12
REVIEW
Lucía Robado de Lope, Olwen Leaman Alcíbar, Ana Amor López, Marta Hergueta-Redondo, Héctor Peinado
During metastasis, tumour cells must communicate with their microenvironment by secreted soluble factors and extracellular vesicles. Different stromal cell types (e.g. bone marrow-derived cells, endothelial cells and fibroblasts) influence the growth and progression of tumours. In recent years, interest has extended to other cell types in the tumour microenvironment such as adipocytes and adipose tissue-derived mesenchymal stem cells. Indeed, obesity is becoming pandemic in some developing countries and it is now considered to be a risk factor for cancer progression...
January 5, 2018: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
https://www.readbyqxmd.com/read/29158255/nitro-fatty-acid-inhibition-of-triple-negative-breast-cancer-cell-viability-migration-invasion-and-tumor-growth
#13
Chen-Shan Chen Woodcock, Yi Huang, Steven R Woodcock, Sonia R Salvatore, Bhupinder Singh, Franca Golin-Bisello, Nancy E Davidson, Carola Neumann, Bruce A Freeman, Stacy G Wendell
Triple negative breast cancer (TNBC) comprises ~20% of all breast cancers and is the most aggressive mammary cancer subtype. Devoid of the estrogen and progesterone receptors, along with the receptor tyrosine kinase ERB2 (HER2) that define most mammary cancers, there are no targeted therapies for patients with TNBC. This, combined with a high metastatic rate and a lower 5-year survival rate than for other breast cancer phenotypes, means there is significant unmet need for new therapeutic strategies. Herein, the anti-neoplastic effects of the electrophilic fatty acid nitroalkene derivative, 10-nitro-octadec-9-enoic acid (nitro-oleic acid, NO2-OA), were investigated in multiple preclinical models of TNBC...
November 20, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29156913/symptom-clusters-using-the-brief-pain-inventory-in-patients-with-breast-cancer
#14
Vithusha Ganesh, Leah Drost, Nicholas Chiu, Liying Zhang, Leonard Chiu, Ronald Chow, Nicholas Lao, Bo Angela Wan, Justin Lee, Edward Chow, Carlo DeAngelis
BACKGROUND: The purpose of this study was to assess symptom clusters in functional interference using the brief pain inventory (BPI) in patients with non-metastatic breast cancer (BC) during and after chemotherapy. METHODS: A principal component analysis with varimax rotation was conducted on data from 228 patients to identify two clusters at baseline and two intervals following treatment. RESULTS: Physical (general activity, normal work, walking ability) and psychosocial (mood, relationships, sleep, enjoyment of life) interference clusters were present at baseline...
October 18, 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29156892/trastuzumab-emtansine-in-her2-positive-metastatic-breast-cancer-what-is-the-best-sequence
#15
EDITORIAL
Francesco Ricci, Christophe Le Tourneau
No abstract text is available yet for this article.
November 6, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156807/halofuginone-inhibits-tgf-%C3%AE-bmp-signaling-and-in-combination-with-zoledronic-acid-enhances-inhibition-of-breast-cancer-bone-metastasis
#16
Patricia Juárez, Pierrick G J Fournier, Khalid S Mohammad, Ryan C McKenna, Holly W Davis, Xiang H Peng, Maria Niewolna, Alain Mauviel, John M Chirgwin, Theresa A Guise
More efficient therapies that target multiple molecular mechanisms are needed for the treatment of incurable bone metastases. Halofuginone is a plant alkaloid-derivative with antiangiogenic and antiproliferative effects. Here we demonstrate that halofuginone is an effective therapy for the treatment of bone metastases, through multiple actions that include inhibition of TGFβ and BMP-signaling. Halofuginone blocked TGF-β-signaling in MDA-MB-231 and PC3 cells showed by inhibition of TGF-β-induced Smad-reporter, phosphorylation of Smad-proteins, and expression of TGF-β-regulated metastatic genes...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156693/cdk3-target-of-mir-4469-suppresses-breast-cancer-metastasis-via-inhibiting-wnt-%C3%AE-catenin-pathway
#17
Ting Cao, Tian Xiao, Guanqun Huang, Yafei Xu, Joe Jiang Zhu, Kaixin Wang, Wencai Ye, Hong Guan, Jinsong He, Duo Zheng
Cyclin-dependent kinase 3 (CDK3), a member of CDK family, is involved in G0/G1 and G1/S cell cycle transitions. Although several researchers discovered that CDK3 related to cell growth in some kinds of cancer, the functions of CDK3 during tumor development remains unclear. Here, we first found that the expression of CDK3 was higher in primary tumors of non-metastatic breast cancer compared with those in metastatic breast cancer. Overexpression of CDK3 suppressed cell migration and invasion of breast cancer cells, and decreased the metastasis in nude mice...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156384/targeting-fgfr-pathway-in-breast-cancer
#18
J Perez-Garcia, E Muñoz-Couselo, J Soberino, F Racca, J Cortes
Developments in breast cancer biology over the last years have permitted deconstructing the molecular profile of the most relevant breast cancer subtypes. This has led to an increase in therapeutic options, including more effective personalized therapy for breast cancer and substantial improvements in patient outcomes. Although currently there are only a few targeted therapies approved for metastatic breast cancer, the discovery of druggable kinase gene alterations has radically changed cancer treatment by providing novel and successfully actionable drug targets...
November 17, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29155017/p-glycoprotein-mdr1-abcb1-and-breast-cancer-resistance-protein-bcrp-abcg2-affect-brain-accumulation-and-intestinal-disposition-of-encorafenib-in-mice
#19
Jing Wang, Changpei Gan, Rolf W Sparidans, Els Wagenaar, Stéphanie van Hoppe, Jos H Beijnen, Alfred H Schinkel
Encorafenib (LGX818) is a promising BRAF(V600E) inhibitor that has efficacy against metastatic melanoma. To better understand its pharmacokinetics, we studied its interactions with the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug metabolizing enzyme CYP3A. In polarized MDCK-II cells, encorafenib was efficiently transported by canine and human ABCB1 and ABCG2 and by mouse Abcg2. Upon oral administration to wild-type, Abcb1a/1b(-/-), Abcg2(-/-), and Abcb1a/1b;Abcg2(-/-) mice, encorafenib was absorbed very quickly and to very high plasma levels, but without clear changes in oral availability between the strains...
November 14, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29153866/a-phase-i-trial-of-the-pi3k-inhibitor-buparlisib-combined-with-capecitabine-in-patients-with-metastatic-breast-cancer
#20
Autumn J McRee, Paul K Marcom, Dominic T Moore, William C Zamboni, Zachary A Kornblum, Zhiyuan Hu, Rachel Phipps, Carey K Anders, Katherine Reeder-Hayes, Lisa A Carey, Karen E Weck, Charles M Perou, E Claire Dees
BACKGROUND: Buparlisib is an oral pan-class I phosphotidyinositol-3-kinase (PI3K) inhibitor. The present phase I study evaluated the safety, pharmacokinetics, and efficacy of buparlisib with capecitabine in patients with metastatic breast cancer. PATIENTS AND METHODS: Patients received buparlisib once daily (range, 50 to 100 mg) for 3 weeks with capecitabine twice daily (range, 1000 to 1250 mg/m(2)) for 2 weeks with a 1-week break. Dose escalation used a traditional "3 + 3" design with standard definitions of dose-limiting toxicity (DLT) and maximum tolerated dose...
October 28, 2017: Clinical Breast Cancer
keyword
keyword
62249
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"